Live Breaking News & Updates on Induction Study

Stay updated with breaking news from Induction study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

InDex Pharmaceuticals announces expected cash balance per March 31, 2024

InDex Pharmaceuticals announces expected cash balance per March 31, 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan Klotter , Jenny Sundqvist , Johan Gil , Index Pharmaceuticals Holding , Kindex Pharmaceuticals , Prnewswire Index Pharmaceuticals Holding , Dex Pharmaceuticals , Induction Study , Abuse Regulation , Nasdaq First North Growth Market , Addex Pharma , Die Performance Strategie , Assets Sie ,

Gastroenterology Month in Review: November 2023

November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors. ....

North Carolina , United States , Data Monitoring Committee , Kindex Pharmaceuticals , Phathom Pharmaceutical , Data Monitoring , Induction Study , Case Safety Reports , C Diff , Clostridioides Difficile , Erosive Esophagitis ,

InDex Pharmaceuticals discontinues cobitolimod phase III program

InDex Pharmaceuticals discontinues cobitolimod phase III program
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Jenny Sundqvist , Johan Gil , Prnewswire Index Pharmaceuticals Holding , Data Monitoring Committee , Index Pharmaceuticals Holding , Kindex Pharmaceuticals , Dex Pharmaceuticals , Induction Study , Abuse Regulation , Nasdaq First North Growth Market ,

InDex Scraps Phase III Ulcerative Colitis Trial on Disappointing Data

After a negative review by an Independent Data Monitoring Committee, InDex Pharmaceuticals has decided to discontinue the late-stage CONCLUDE program evaluating its cobitolimod in ulcerative colitis. ....

Eli Lilly Omvoh , Jenny Sundqvist , Data Monitoring Committee , Televant Holdings , Index Pharmaceuticals On , Dex Pharmaceuticals , Independent Data Monitoring Committee , Induction Study , Eli Lilly , Ndex Scraps Phase Iii Ulcerative Colitis Trial On Disappointing Data ,

Cobitolimod Phase 3 Program Discontinued for Ulcerative Colitis Treatment

This phase 3 program was advised to discontinue given that cobitolimod was shown to be less likely to meet its primary endpoint. ....

Jenny Sundqvist , Kindex Pharmaceuticals , Data Monitoring Committee , Induction Study , Dex Pharmaceuticals , Ulcerative Colitis , Phase 3 ,